

PTO/SB/03a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	09/928,122
---------------------------	-------------------

Filing Date	08/10/2001
--------------------	------------

<i>First Named Inventor</i>	J. Guy BREITENBUCHER
-----------------------------	-------------------------

Group Art Unit	1624
----------------	------

Examiner Name	EMILY B. BERNHARDT
---------------	--------------------

Attorney Docket Number	ORT 1478
------------------------	----------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature	<i>R. Rasmussen</i>	Date Considered	4-11-09
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/928,122
Filing Date	08/10/2001
First Named Inventor	J. Guy BREITENBUCHER
Group Art Unit	1624
Examiner Name	EMILY B. BERNHARDT
Attorney Docket Number	ORT 1478

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T ²
RR		CHAPMAN, H.A. et al., "Emerging Roles for Cysteine Proteases in Human Biology"; Annu. Rev. Physiol. (1997) 59:63-88.	No	
RR		CHAPMAN, H.A. et al., "Endosomal Proteolysis and MHC Class II Function"; Curr. Opin. in Immunol. (1998) 10:93-102.	No	
RR		GAGA, et al., "Eosinophil Activation and T Lymphocyte Infiltration in Allergen-Induced Late Phase Skin Reactions and Classical Delayed-Type Hypersensitivity" Journal. Immun. (1991) 147:816-822.	No	
RR		MAURER, D. et al., "Fcε Receptor I on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S-Dependent Pathway of MHC Class II Presentation" J. Immunol. (1998) 161:2731-2739.	No	
RR		NAKAGAWA, T.Y. et al., "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice"; Immunity (1999) 10:207-217	No	
RR		NAKAGAWA, T.Y. et al., "The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation" Immunological Rev. (1999) 172:121-129.	No	
RR		PALUCHOWSKA, et al., Polish J. Pharmacology 51(5), 415-421 (1999) "Structure-Activity Relationship Studies of CNS Agents part 40. "EFFECT OF THE AMIDE FRAGMENT ON 5-HT _{1A} RECEPTOR ACTIVITY OF SOME ANALOGS OF MP 3022"	No	
RR		PALUCHOWSKA, et al., Polish J. Pharmacology 52(3), 209-216 (2000) "INFLUENCE OF THE ALIPHATIC SPACER LENGTH ON THE 5-HT _{1A} RECEPTOR ACTIVITY OF NEW ARYLPIPERAZINES WITH AN INDAZOLE SYSTEM"	No	
RR		RIESE, R.J. et al., "Cathepsin S Activity Regulates Antigen Presentation and Immunity"; J. Clin Invest. (1998) 101 (11):2351-2363	No	
RR		RIESE, R.J. et al., "Cathepsins and Compartmentalization in Antigen Presentation; Curr. Opin. Immunol. (2000) 12:107-113	No	
RR		RIESE, R.J. et al., "Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading; Immunity (1996) 4:357-366.	No	
RR		VILLADANGOS, J.A. et al., "Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism" J. Exp. Med. (1997) 186(4):549-560.	No	
RR		VILLADANGOS, J.A. et al., "Proteases Involved in MHC Class II Antigen Presentation" Immunological Rev. (1999) 172:109-120.	No	
RR		VILLADANGOS, J.A. et al., "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?"; Immunity (2000) 12:233-239.	No	

Examiner
Signature

RR [Signature]

Date
Considered

4-11-09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.